@article{Fish_M-2022_96057,
title = {Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial},
author = {Fish, M. and Rynne, J. and Jennings, A. and Lam, C. and Lamikanra, A. and Ratcliff, J. and Cellone-Trevelin, S. and Timms, E. and Jeriha, J. and Tosi, I. and Pramanik, R. and Simmonds, P. and Seth, S. and Williams, J. and Gordon, A. and Knight, J. and Smith, D. and Whalley, J. and Harrison, D. and Rowan, K. and Harvala, H. and Klenerman, P. and Estcourt, L. and Menon, D. and Roberts, D. and Shankar-Hari, M. and REMAP-CAP Immunoglobulin Domain UK Investigators},
month = {sep},
year = {2022},
abstract = {Purpose: Benefit from convalescent plasma therapy for coronavirus disease 2019 (COVID19) has been inconsistent in randomized clinical trials (RCTs) involving critically ill patients. As COVID-19 patients are immunologically heterogeneous, we hypothesized that immunologically similar COVID-19 subphenotypes may differ in their treatment responses to convalescent plasma and explain inconsistent findings between RCTs.},
journal = {Intensive Care Medicine},
publisher = {Springer Nature},
url = {https://doi.org/10.1007/s00134-022-06869-w},
}
